Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.
The compound, called F6, has been potent against antibiotic-resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), which is often found in hospitals and other health care settings, and vancomycin-resistant Staphylococcus aureus (VRSA), with vancomycin long considered a drug of last resort. The compound was tested against clinical isolates.
“This is very exciting,” said Herman Sintim, drug discovery professor in Purdue’s Department of Chemistry. “We are not the first to report of a new molecular entity that killed these drug-resistant pathogens. But what is unique about the compound that we found is that when we tried to generate resistance in the lab, we couldn’t.”
Antibiotic resistance is a growing public health crisis. The World Health Organization has deemed antibiotic resistance one of the three greatest threats to human health because bacteria are becoming increasingly resistant and too few treatments are being developed. The Centers for Disease Control and Prevention reports that at least 2 million people a year in the United States become infected with bacteria resistant to antibiotics and at least 23,000 people die a year as a result. Studies have estimated that drug-resistant infections could be responsible for 10 million deaths a year worldwide by 2050.
Pharmaceutical companies have been reluctant to invest in antibiotics because it typically costs millions of dollars to develop a drug and the probability of bacterial resistance is high.
Purdue researchers identified F6 by screening a chemical library for compounds with antibacterial activity. They tried to force bacteria resistance on F6, performing experiments to evaluate the ability of MRSA USA400 to develop resistance to F6 in vitro.
“The idea is that if you keep adding increasing concentrations to bacteria and then you keep regrowing the bacteria, after so many cycles you are going to develop resistance,” Sintim said. “Scientists do this to figure out whether whatever they have created develops resistance quickly.”
The minimal inhibitory concentration, or MIC, remained unchanged for F6 over nine passages and doubled on the10th passage. It then remained unchanged up to the 14th passage during a two-week period. By comparison, the MIC of the antibiotic ciprofloxacin tripled after the eighth passage and continued to rapidly increase to more than 2,000-fold by the 14th passage.
“We are not saying there will never be resistance to the F6 molecule or analogs thereof. What we are saying is that here is a new molecule that works and when we try to force resistance we couldn’t generate resistance,” Sintim said.
F6, which is nontoxic to humans and other mammals, works against bacteria in a group known as Gram-positive, but not against those that are Gram-negative. F6 was effective against MRSA, VRSA, Enterococcus faecalis, which lives in the human gut, vancomycin-resistant Enterococcus (VRE) and Listeria monocytogenes, often associated with unpasteurized dairy products.
Testing on mice also indicated F6 was as effective as fusidic acid in treating a wound infected with MRSA, further confirming its potent antibacterial effect.
The Purdue researchers will now begin to make derivatives of F6 to see if they might be even more effective. They are working with the Purdue Office of Technology Commercialization to look for partners to help further develop this exciting new molecular entity.
The Latest on: Antibiotic-resistant pathogens
via Google News
The Latest on: Antibiotic-resistant pathogens
- analytica conference 2020 for the first time virtual: New approaches in the fight against antibiotic resistanceon October 8, 2020 at 1:53 am
Current questions and approaches in analysis are in the focus of the analytica conference, which will take place from October 19 to 23, 2020, in the context of analytica virtual in a purely digital ...
- T2 Biosystems announces $10.5M contract optionon October 7, 2020 at 9:07 am
Lexington-based T2 Biosystems Inc., which works in the field of rapid detection of sepsis-causing pathogens, announced that the Biomedical Advanced ...
- CPD: Don’t make a dog’s dinner – maintaining health and safety when cleaning streetson October 2, 2020 at 3:32 am
As all these pathogens are transmitted via a faecal-oral route ... Clinically relevant, and in some cases, antibiotic-resistant bacteria can be transmitted to people as a result of direct exposure or ...
- Fact check: People have not been developing antibiotic-resistant pneumonia from wearing face maskson October 1, 2020 at 10:02 pm
Secondly, once relevant pathogens have been inhaled ... where health care workers are most prone to antibiotic-resistant bacteria.” While it is false to say people are developing pneumonia ...
- T2 Biosystems Announces BARDA Exercise of Contract Option 1 Valued at $10.5 Millionon September 30, 2020 at 6:00 am
The first option was exercised under the multi-year contract between BARDA and T2 Biosystems, valued at up to $69.0 million if all options are exercised, following the Company’s successful completion ...
- Recce Pharmaceuticals and Murdoch Children’s Research Institute to Evaluate RECCE® 435 Against ...on September 30, 2020 at 5:53 am
Murdoch Children’s Research Institute to evaluate the in-vivo antimicrobial activity of RECCE® 435 oral formulation against Helicobacter pylori (H. pylori) in preclinical studies program Studies led ...
- Antimicrobial polymer kills drug-resistant pathogens time after timeon September 29, 2020 at 5:00 pm
The researchers tested the polymer against six types of bacteria, including three antibiotic-resistant strains ... antimicrobial surfaces for use in the fight against drug-resistant pathogens and ...
- Aptorum Shares Skyrocket Upon Launching Infectious Disease Liquid Biopsy Uniton September 29, 2020 at 2:00 pm
are "to rapidly and accurately identify and detect existing or emerging unknown pathogens (including DNA/RNA-based viruses such as coronavirus, antibiotic-resistant bacteria and fungi) in a ...
- Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular ...on September 29, 2020 at 3:00 am
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on nov ...
via Bing News